WallStSmart

Vertex Pharmaceuticals Inc (VRTX)vsWipro Limited ADR (WIT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Wipro Limited ADR generates 7474% more annual revenue ($908.92B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 14.6%. VRTX appears more attractively valued with a PEG of 2.19. VRTX earns a higher WallStSmart Score of 66/100 (B-).

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62

WIT

Buy

53

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 7.3Quality: 7.3
Piotroski: 5/9Altman Z: 3.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued
WITSignificantly Overvalued (-171.6%)

Margin of Safety

-171.6%

Fair Value

$0.88

Current Price

$2.09

$1.21 premium

UndervaluedFair: $0.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

WIT4 strengths · Avg: 9.0/10
Free Cash FlowQuality
$37.93B10/10

Generating 37.9B in free cash flow

Altman Z-ScoreHealth
3.5210/10

Safe zone — low bankruptcy risk

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Areas to Watch

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WIT2 concerns · Avg: 3.0/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

EPS GrowthGrowth
-7.2%2/10

Earnings declined 7.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bull Case : WIT

The strongest argument for WIT centers on Free Cash Flow, Altman Z-Score, P/E Ratio.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : WIT

The primary concerns for WIT are PEG Ratio, EPS Growth.

Key Dynamics to Monitor

VRTX profiles as a mature stock while WIT is a value play — different risk/reward profiles.

WIT carries more volatility with a beta of 0.36 — expect wider price swings.

VRTX is growing revenue faster at 9.5% — sustainability is the question.

WIT generates stronger free cash flow (37.9B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 53/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Wipro Limited ADR

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Wipro Limited is a global information technology (IT), consulting and business process services company. The company is headquartered in Bengaluru, India.

Want to dig deeper into these stocks?